Karyopharm announces publication of health-related quality of life outcomes from phase 3 seal study of selinexor in advanced unresectable dedifferentiated liposarcoma in future oncology

Newton, mass., april 19, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that health-related quality of life (hrqol) data from the phase 3 portion of the seal ( se linexor in a dvanced l iposarcoma) study were published online in future oncology.
KPTI Ratings Summary
KPTI Quant Ranking